{"product_id":"international-myeloma-society-7th-immune-effector-cell-therapies-in-multiple-myeloma-workshop-2026","title":"International Myeloma Society 7th Immune Effector Cell Therapies in Multiple Myeloma Workshop 2026","description":"\u003ch1\u003eInternational Myeloma Society (IMS) 7th Immune Effector Cell Therapies in Multiple Myeloma Workshop 2026 (Videos)\u003c\/h1\u003e\r\n\u003ch2\u003eAdvanced Updates in CAR T-Cell Therapy, Bispecific \u0026amp; Trispecific Antibodies, BCMA-Targeted Therapies, Cellular Immunotherapy, and Precision Treatment for Multiple Myeloma\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eStay at the cutting edge of cellular immunotherapy with the \u003cstrong\u003eInternational Myeloma Society (IMS) 7th Immune Effector Cell Therapies in Multiple Myeloma Workshop 2026\u003c\/strong\u003e, an advanced continuing medical education (CME) program dedicated to the rapidly evolving field of immune effector cell therapies for multiple myeloma. This internationally recognized workshop brings together leading hematologists, medical oncologists, immunologists, translational researchers, and clinical scientists to present the latest scientific discoveries, clinical trial updates, real-world evidence, and emerging treatment strategies that are reshaping the management of relapsed and refractory multiple myeloma.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eHeld \u003cstrong\u003eMarch 27–28, 2026\u003c\/strong\u003e, at the \u003cstrong\u003eBoston Marriott Long Wharf, Boston, Massachusetts\u003c\/strong\u003e, with both \u003cstrong\u003elive and on-demand access\u003c\/strong\u003e, the workshop delivers comprehensive education on next-generation \u003cstrong\u003eCAR T-cell therapies\u003c\/strong\u003e, \u003cstrong\u003ebispecific antibodies\u003c\/strong\u003e, \u003cstrong\u003etrispecific antibodies\u003c\/strong\u003e, \u003cstrong\u003edual-targeted cellular therapies\u003c\/strong\u003e, \u003cstrong\u003eimmune resistance mechanisms\u003c\/strong\u003e, \u003cstrong\u003etoxicity management\u003c\/strong\u003e, and innovative \u003cstrong\u003ein vivo immune engineering\u003c\/strong\u003e approaches. Through expert-led presentations, translational research updates, and multidisciplinary scientific discussions, participants gain practical knowledge that can be immediately integrated into clinical practice and research.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eDesigned to bridge laboratory discoveries with real-world patient care, this workshop provides clinicians with evidence-based guidance for selecting, sequencing, administering, and monitoring advanced immune therapies while optimizing patient outcomes.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eProduct Details\u003c\/h1\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eCourse:\u003c\/strong\u003e 7th Immune Effector Cell Therapies in Multiple Myeloma Workshop 2026\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eProvider:\u003c\/strong\u003e International Myeloma Society (IMS)\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eConference Dates:\u003c\/strong\u003e March 27–28, 2026\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eLocation:\u003c\/strong\u003e Boston Marriott Long Wharf, Boston, Massachusetts, USA\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Videos (Live \u0026amp; On-Demand)\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eLanguage:\u003c\/strong\u003e English\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eEducational Level:\u003c\/strong\u003e Advanced\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eCourse Overview\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eImmune effector cell therapies have transformed the treatment landscape of multiple myeloma, offering durable responses for patients with relapsed and refractory disease. Rapid advances in \u003cstrong\u003eCAR T-cell therapy\u003c\/strong\u003e, \u003cstrong\u003ebispecific antibodies\u003c\/strong\u003e, \u003cstrong\u003etrispecific antibodies\u003c\/strong\u003e, and novel immune-based strategies continue to redefine standards of care while introducing new clinical challenges related to toxicity, resistance, sequencing, and long-term patient management.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThe \u003cstrong\u003eIMS 7th Immune Effector Cell Therapies in Multiple Myeloma Workshop 2026\u003c\/strong\u003e provides an in-depth review of these rapidly evolving therapies through presentations by internationally recognized experts. Faculty review current clinical trial results, real-world experience, translational research, genomic discoveries, immune microenvironment interactions, and future therapeutic innovations designed to improve efficacy and overcome resistance.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eParticipants gain practical strategies for integrating advanced immune therapies into routine clinical practice while enhancing multidisciplinary collaboration between academic centers and community oncology programs.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eWhat You'll Learn\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eAfter completing this course, participants will be able to:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eEvaluate current evidence supporting CAR T-cell therapies and bispecific antibodies in multiple myeloma.\u003c\/li\u003e\r\n \t\u003cli\u003eCompare available BCMA-targeted and GPRC5D-targeted treatment options.\u003c\/li\u003e\r\n \t\u003cli\u003eInterpret emerging data on trispecific antibodies and dual-targeted CAR T-cell therapies.\u003c\/li\u003e\r\n \t\u003cli\u003eRecognize and manage toxicities associated with immune effector cell therapies.\u003c\/li\u003e\r\n \t\u003cli\u003eUnderstand mechanisms of treatment resistance and immune escape.\u003c\/li\u003e\r\n \t\u003cli\u003eOptimize sequencing strategies for cellular immunotherapies.\u003c\/li\u003e\r\n \t\u003cli\u003eApply translational research findings to precision oncology practice.\u003c\/li\u003e\r\n \t\u003cli\u003eImprove outcomes through individualized immune-based treatment planning.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eComprehensive Topics Covered\u003c\/h1\u003e\r\n\u003ch2\u003eCAR T-Cell Therapy\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eReview the latest developments in CAR T-cell therapy for relapsed and refractory multiple myeloma.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eIde-cel\u003c\/li\u003e\r\n \t\u003cli\u003eCilta-cel\u003c\/li\u003e\r\n \t\u003cli\u003eAnito-cel\u003c\/li\u003e\r\n \t\u003cli\u003eGC012F\u003c\/li\u003e\r\n \t\u003cli\u003eCAR T manufacturing\u003c\/li\u003e\r\n \t\u003cli\u003ePatient selection\u003c\/li\u003e\r\n \t\u003cli\u003eClinical outcomes\u003c\/li\u003e\r\n \t\u003cli\u003eLong-term follow-up\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eFaculty discuss current evidence, real-world experience, and future directions for cellular therapy.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eBispecific Antibodies\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eDevelop a comprehensive understanding of T-cell engaging therapies that are rapidly becoming integral components of myeloma treatment.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eTeclistamab\u003c\/li\u003e\r\n \t\u003cli\u003eTalquetamab\u003c\/li\u003e\r\n \t\u003cli\u003eElranatamab\u003c\/li\u003e\r\n \t\u003cli\u003eLinvoseltamab\u003c\/li\u003e\r\n \t\u003cli\u003eMechanisms of action\u003c\/li\u003e\r\n \t\u003cli\u003eClinical efficacy\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment sequencing\u003c\/li\u003e\r\n \t\u003cli\u003ePatient monitoring\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eTrispecific \u0026amp; Next-Generation Immune Therapies\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eExplore innovative immune strategies currently under investigation.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eTrispecific antibodies\u003c\/li\u003e\r\n \t\u003cli\u003eDual-targeted CAR T cells\u003c\/li\u003e\r\n \t\u003cli\u003eCombination immunotherapy\u003c\/li\u003e\r\n \t\u003cli\u003eIn vivo immune therapies\u003c\/li\u003e\r\n \t\u003cli\u003eEmerging cellular platforms\u003c\/li\u003e\r\n \t\u003cli\u003eFuture therapeutic approaches\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eBCMA \u0026amp; GPRC5D Targeted Therapies\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eUnderstand the biology and clinical application of major therapeutic targets in multiple myeloma.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eBCMA biology\u003c\/li\u003e\r\n \t\u003cli\u003eGPRC5D\u003c\/li\u003e\r\n \t\u003cli\u003eTarget selection\u003c\/li\u003e\r\n \t\u003cli\u003ePrecision medicine\u003c\/li\u003e\r\n \t\u003cli\u003eBiomarker-driven therapy\u003c\/li\u003e\r\n \t\u003cli\u003ePersonalized treatment\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eToxicity Management\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eGain practical guidance for recognizing and managing immune-related adverse events.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCytokine Release Syndrome (CRS)\u003c\/li\u003e\r\n \t\u003cli\u003eImmune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)\u003c\/li\u003e\r\n \t\u003cli\u003eDelayed neurotoxicity\u003c\/li\u003e\r\n \t\u003cli\u003eImmune effector cell enterocolitis\u003c\/li\u003e\r\n \t\u003cli\u003eInfection prevention\u003c\/li\u003e\r\n \t\u003cli\u003eSupportive care\u003c\/li\u003e\r\n \t\u003cli\u003eLong-term monitoring\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eFaculty provide evidence-based recommendations for improving patient safety while maximizing therapeutic benefit.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eResistance Mechanisms\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eReview the biological mechanisms responsible for treatment resistance and relapse.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eGenomic alterations\u003c\/li\u003e\r\n \t\u003cli\u003eClonal evolution\u003c\/li\u003e\r\n \t\u003cli\u003eImmune escape\u003c\/li\u003e\r\n \t\u003cli\u003eTumor microenvironment\u003c\/li\u003e\r\n \t\u003cli\u003eAntigen loss\u003c\/li\u003e\r\n \t\u003cli\u003eResistance biomarkers\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eParticipants learn strategies for overcoming resistance through novel therapeutic approaches.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eTranslational Medicine\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eBridge laboratory discoveries with clinical implementation.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eTranslational research\u003c\/li\u003e\r\n \t\u003cli\u003ePrecision oncology\u003c\/li\u003e\r\n \t\u003cli\u003eBiomarker development\u003c\/li\u003e\r\n \t\u003cli\u003eClinical trials\u003c\/li\u003e\r\n \t\u003cli\u003eEmerging technologies\u003c\/li\u003e\r\n \t\u003cli\u003eFuture immunotherapies\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eClinical Implementation\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eDevelop practical strategies for integrating immune therapies into everyday oncology practice.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eTreatment sequencing\u003c\/li\u003e\r\n \t\u003cli\u003ePatient selection\u003c\/li\u003e\r\n \t\u003cli\u003eReferral pathways\u003c\/li\u003e\r\n \t\u003cli\u003eMultidisciplinary care\u003c\/li\u003e\r\n \t\u003cli\u003eReal-world clinical practice\u003c\/li\u003e\r\n \t\u003cli\u003eCommunity oncology integration\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eLearning Objectives\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eUpon completion of this educational activity, participants will be able to:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eEvaluate current clinical evidence for CAR T-cell therapies and bispecific antibodies.\u003c\/li\u003e\r\n \t\u003cli\u003eCompare novel immune therapeutic platforms including trispecific antibodies and dual-targeted CAR T cells.\u003c\/li\u003e\r\n \t\u003cli\u003eRecognize and manage toxicities associated with immune effector cell therapies.\u003c\/li\u003e\r\n \t\u003cli\u003eUnderstand genomic and microenvironmental mechanisms of resistance.\u003c\/li\u003e\r\n \t\u003cli\u003eApply practical treatment sequencing strategies for modern immune therapies.\u003c\/li\u003e\r\n \t\u003cli\u003eIntegrate translational research into evidence-based patient care.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eEducational Highlights\u003c\/h1\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eMultiple Myeloma\u003c\/li\u003e\r\n \t\u003cli\u003eCAR T-Cell Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eCellular Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eBCMA-Targeted Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eGPRC5D\u003c\/li\u003e\r\n \t\u003cli\u003eBispecific Antibodies\u003c\/li\u003e\r\n \t\u003cli\u003eTrispecific Antibodies\u003c\/li\u003e\r\n \t\u003cli\u003eT-Cell Engagers\u003c\/li\u003e\r\n \t\u003cli\u003ePrecision Oncology\u003c\/li\u003e\r\n \t\u003cli\u003eTranslational Medicine\u003c\/li\u003e\r\n \t\u003cli\u003eImmunotherapy\u003c\/li\u003e\r\n \t\u003cli\u003eImmune Effector Cell Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eCytokine Release Syndrome (CRS)\u003c\/li\u003e\r\n \t\u003cli\u003eICANS\u003c\/li\u003e\r\n \t\u003cli\u003eNeurotoxicity\u003c\/li\u003e\r\n \t\u003cli\u003eTumor Microenvironment\u003c\/li\u003e\r\n \t\u003cli\u003eResistance Mechanisms\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Trials\u003c\/li\u003e\r\n \t\u003cli\u003eReal-World Evidence\u003c\/li\u003e\r\n \t\u003cli\u003eContinuing Medical Education (CME)\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eWhy This Course Stands Out\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThe \u003cstrong\u003eInternational Myeloma Society 7th Immune Effector Cell Therapies in Multiple Myeloma Workshop 2026\u003c\/strong\u003e represents one of the world's premier scientific meetings dedicated exclusively to immune therapies for multiple myeloma. Combining internationally recognized experts, cutting-edge translational research, real-world clinical experience, and practical implementation strategies, the program provides an exceptional review of current and future immune-based therapies. Its emphasis on treatment sequencing, toxicity management, resistance biology, and emerging cellular technologies makes it an indispensable educational resource for clinicians and researchers involved in modern myeloma care.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eTarget Audience\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThis educational activity is ideal for:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eHematologists\u003c\/li\u003e\r\n \t\u003cli\u003eMedical Oncologists\u003c\/li\u003e\r\n \t\u003cli\u003eImmunologists\u003c\/li\u003e\r\n \t\u003cli\u003eHematopathologists\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Researchers\u003c\/li\u003e\r\n \t\u003cli\u003eTranslational Scientists\u003c\/li\u003e\r\n \t\u003cli\u003eHematology Fellows\u003c\/li\u003e\r\n \t\u003cli\u003eOncology Fellows\u003c\/li\u003e\r\n \t\u003cli\u003eCellular Therapy Specialists\u003c\/li\u003e\r\n \t\u003cli\u003eBone Marrow Transplant Physicians\u003c\/li\u003e\r\n \t\u003cli\u003eAdvanced Practice Providers\u003c\/li\u003e\r\n \t\u003cli\u003eHealthcare Professionals involved in the diagnosis and treatment of multiple myeloma\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eWhy Choose This Course?\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eWhether you specialize in hematology, oncology, immunotherapy, or translational cancer research, the \u003cstrong\u003eInternational Myeloma Society 7th Immune Effector Cell Therapies in Multiple Myeloma Workshop 2026\u003c\/strong\u003e delivers an outstanding evidence-based review of the latest advances in immune-based treatment for multiple myeloma. Featuring internationally recognized faculty, cutting-edge clinical trial updates, practical toxicity management, translational science, and emerging therapeutic innovations, this program equips clinicians with the knowledge needed to confidently implement next-generation immunotherapies and improve outcomes for patients with plasma cell disorders.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003e\u003c\/h2\u003e\r\n\u003cp data-path-to-node=\"6\"\u003e\u003cb data-path-to-node=\"6\" data-index-in-node=\"0\"\u003eTopics\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"7\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,0,0\"\u003e\u003cb data-path-to-node=\"7,0,0\" data-index-in-node=\"0\"\u003eSESSION 1: CLINICAL UPDATES ON CART CELLS\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"7,0,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,0,1,0,0\"\u003eIde-cel and Cilta-cel: Latest Updates and Ongoing Trials\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,0,1,1,0\"\u003eLatest Real World Data for CAR T Cells\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,0,1,2,0\"\u003eUpdate on Anito-cel and GC012F\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,0,1,3,0\"\u003eGPRC5D CAR T Cells: Latest Updates and Ongoing Trials\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,0,1,4,0\"\u003eDual-targeted CAR T Cell Approaches\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,0,1,5,0\"\u003eUpdate on Allogeneic CAR T Cell Approaches\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,1,0\"\u003e\u003cb data-path-to-node=\"7,1,0\" data-index-in-node=\"0\"\u003eSESSION 2: CLINICAL UPDATES ON BISPECIFIC ANTIBODIES\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"7,1,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,1,1,0,0\"\u003eTeclistamab and Talquetamab for Relapsed MM: Latest Updates and Ongoing Trials\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,1,1,1,0\"\u003eElranatamab and Linvoseltamab for Relapsed MM: Latest Updates and Ongoing Trials\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,1,1,2,0\"\u003eReal World Data for Bispecific Antibodies\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,1,1,3,0\"\u003eBispecific Abs for First-line and Maintenance Therapy\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,1,1,4,0\"\u003eEtentamig and Cevostamab: Latest Updates and Ongoing Trials\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,2,0\"\u003e\u003cb data-path-to-node=\"7,2,0\" data-index-in-node=\"0\"\u003eSESSION 3: NOVEL APPROACHES IN THE CLINIC\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"7,2,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,2,1,0,0\"\u003eTrispecific Antibodies for Myeloma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,2,1,1,0\"\u003eCombining Bispecific Abs with CAR T Cells\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,2,1,2,0\"\u003eFixed Duration Bispecific Antibody Therapy\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,2,1,3,0\"\u003eAugmenting T Cell Therapies with Proteasome Inhibitors\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,2,1,4,0\"\u003eTriPRIL CAR T Cells\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,2,1,5,0\"\u003eBispecific with Anti-CD38 Antibody\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,3,0\"\u003e\u003cb data-path-to-node=\"7,3,0\" data-index-in-node=\"0\"\u003eSESSION 4: TOXICITIES OF T CELL ENGAGING THERAPIES\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"7,3,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,3,1,0,0\"\u003ePre-treatment Parameters Predicting CAR T Cell Toxicities\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,3,1,1,0\"\u003eElevated ALC and CAR T Cell Toxicities\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,3,1,2,0\"\u003eManaging CAR-T-associated Delayed Neurotoxicity\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,3,1,3,0\"\u003eCAR T-related Lymphomas: Clinical and Mechanistic Insights\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,4,0\"\u003e\u003cb data-path-to-node=\"7,4,0\" data-index-in-node=\"0\"\u003eSESSION 5: PRACTICAL CONSIDERATIONS FOR IMMUNE THERAPIES\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"7,4,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,4,1,0,0\"\u003eSequencing BCMA-directed Therapies: How to Choose?\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,4,1,1,0\"\u003eOptimizing Outpatient Bispecific Ab and CAR T Cell Administration\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,4,1,2,0\"\u003eManaging Extramedullary Disease with T cell-redirecting Therapies\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,4,1,3,0\"\u003eT Cell Therapies for CNS Myeloma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,4,1,4,0\"\u003eImpact of CHIP on Outcomes after CAR T Cell Therapy\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,5,0\"\u003e\u003cb data-path-to-node=\"7,5,0\" data-index-in-node=\"0\"\u003eSESSION 6: UNDERSTANDING RESPONSE AND RESISTANCE TO T CELL THERAPIES\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"7,5,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,5,1,0,0\"\u003eGenomic Drivers of Resistance to BCMA-targeted Therapies\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,5,1,1,0\"\u003eMechanisms of Antigen Escape following GPRC5D-targeted Therapies\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,5,1,2,0\"\u003eImmune Correlates of Response to BCMA CAR T Cells\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,5,1,3,0\"\u003eMicroenvironmental Factors Impacting Response\/resistance\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,5,1,4,0\"\u003eImmune Correlates of Resistance to Bispecific Antibodies\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,6,0\"\u003e\u003cb data-path-to-node=\"7,6,0\" data-index-in-node=\"0\"\u003eSESSION 7: STRATEGIES TO IMPROVE IMMUNE EFFECTOR CELL THERAPY, PART 1\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"7,6,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,6,1,0,0\"\u003eEvaluating Immune Fitness Across the Stages of MM Progression\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,6,1,1,0\"\u003eTargeting S100A8\/9 to Enhance T Cell Therapies\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,6,1,2,0\"\u003eOvercoming T Cell Exhaustion\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,6,1,3,0\"\u003eModulating the Microbiome to Enhance CAR T Cell Therapy\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,7,0\"\u003e\u003cb data-path-to-node=\"7,7,0\" data-index-in-node=\"0\"\u003eSESSION 8: STRATEGIES TO IMPROVE IMMUNE EFFECTOR CELL THERAPY, PART 2\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"7,7,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,7,1,0,0\"\u003eNovel T Cell Therapy Targets for Myeloma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,7,1,1,0\"\u003eCAR T Cells Against CD70\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,7,1,2,0\"\u003eTargeting Intra-cellular Targets\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,7,1,3,0\"\u003eEZH1\/2 inhibition to augment cellular therapy\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,7,1,4,0\"\u003eEngingeering of First in Class CAR Bugs for Cancer Immunotherapy\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,8,0\"\u003e\u003cb data-path-to-node=\"7,8,0\" data-index-in-node=\"0\"\u003eSESSION 9: CHALLENGING CASES IN IMMUNE EFFECTOR CELL THERAPY\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"7,8,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,8,1,0,0\"\u003eCAR T Cell Therapy in a Patient with Plasma Cell Leukemia\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,8,1,1,0\"\u003eImmune Effector Cell Enterocolitis: A Novel Clonal Lymphoproliferative Disorder?\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,8,1,2,0\"\u003eFatal HLH Following GPRC5D×CD3 Therapy: Lessons from Genetic and Infectious Co-factors\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,9,0\"\u003e\u003cb data-path-to-node=\"7,9,0\" data-index-in-node=\"0\"\u003eSESSION 10: IN VIVO APPROACHES\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"7,9,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,9,1,0,0\"\u003eScience of In Vivo CAR T Cell Therpay\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,9,1,1,0\"\u003eBedside CAR T Cell Production\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,9,1,2,0\"\u003eIn Vivo Bispecific Therapy\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,9,1,3,0\"\u003eClinical Results of In Vivo CAR T Cell Therapy\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"7,9,1,4,0\"\u003eClinical Results of In Vivo CAR T Cell Therapy Part II\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"Meducourse","offers":[{"title":"Default Title","offer_id":43163708850274,"sku":"MED-AMB09615","price":40.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/International-Myeloma-Society-7th-Immune-Effector-Cell-Therapies-in-Multiple-Myeloma-Workshop-2026.jpg?v=1785419453","url":"https:\/\/meducourse.com\/products\/international-myeloma-society-7th-immune-effector-cell-therapies-in-multiple-myeloma-workshop-2026","provider":"Meducourse","version":"1.0","type":"link"}